The FDA has announced an initiative aimed at speeding up the clinical trial process, which includes real-time data reviews.
This new approach involves pharmaceutical companies AstraZeneca and Amgen, who are participating in these enhanced trial processes.
Additionally, the Supreme Court is set to hear a significant case regarding the use of 'skinny labels', which could have implications for the pharmaceutical industry.